New drug B001 tested for rare autoimmune disease

NCT ID NCT05145361

Recruiting now Disease control Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tests a new drug called B001 in 45 people with a rare autoimmune disease called NMOSD. The study aims to check if B001 is safe, how the body processes it, and whether it might help control the disease. Participants must have had at least one relapse in the past year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: B001 injection
What this could lead to: If successful, this could point toward a new treatment option to control NMOSD and reduce relapses.
What could go wrong: This is a very early, small Phase 1b trial focused on safety and dosing. It may not show clear benefit, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NMO SPECTRUM DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuromyelitis optica

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NMO SPECTRUM DISORDER

Contacts and locations

Locations

Beijing Tiantan Hospital Capital Medical University
RECRUITING

Beijing, Beijing Municipality, 100050, China
First Hospital of Shanxi Medical University
RECRUITING

Taiyuan, Shanxi, 030001, China
Tangdu hospital,fourth military medical university
RECRUITING

Xi’an, Shanxi, 710038, China
Tianjin Medical University General Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.